Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322062 | 1.00 | RAB9A (0.73) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL29812424 | 0.92 | RAB9A (0.71) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL3880196 | 0.90 | RAB9A (0.69) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL3881493 | 0.90 | RAB9A (0.65) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL11421677 | 0.89 | RAB9A (0.68) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL7514231 | 0.89 | L3MBTL1 (0.68) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL3895200 | 0.89 | RAB9A (0.68) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL11421680 | 0.89 | RAB9A (0.68) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL11421678 | 0.89 | RAB9A (0.68) | RAB9AL3MBTL1NPC1TDP1GAA | |
| SCHEMBL7514226 | 0.89 | L3MBTL1 (0.68) | RAB9AL3MBTL1NPC1TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4143049-A | METHOD FOR PREPARING 2H-TETRAZOLIUM CHLORIDE AND 2H-TETRAZOLIUM CHLORIDE HYDROCHLORIDE | OSTROVSKAYA VERA M | 1979-03-06 | — | — | US | claimed |
| US-3990947-A | Composition for detecting fibrinogen, fibrinogen split products and fibrin split products | WARNER-LAMBERT COMPANY (US) | 1976-11-09 | — | — | US | claimed |
| US-12600800-B2 | Therapeutic use of mitochondria and combined mitochondrial agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12599429-B2 | Methods for controlling treatment volumes, thermal gradients, muscle stimulation, and immune responses in pulsed electric field treatments | NORTH CAROLINA STATE UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260041481-A1 | METHODS FOR CONTROLLING TREATMENT VOLUMES, THERMAL GRADIENTS, MUSCLE STIMULATION, AND IMMUNE RESPONSES IN PULSED ELECTRIC FIELD TREATMENTS | UNIV NORTH CAROLINA STATE (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014293-A1 | HEMOSTATIC AGENT IN PASTE FORM, USE THEREOF, AND METHOD FOR PRODUCING A LOCAL ACTIVE AGENT RELEASE SYSTEM | HERAEUS MEDICAL GMBH (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-4678196-A1 | PASTY HAEMOSTYPTIC, ITS USE AND A METHOD FOR THE PREPARATION OF A LOCAL DRUG DELIVERY SYSTEM | Heraeus Medical GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4653048-A2 | THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS | The Children's Medical Center Corporation (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4272834-B1 | THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS | CHILDRENS MEDICAL CT CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250019650-A1 | NEURAL CELL EXTRACELLULAR VESICLES | ARUNA BIO, INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-12168700-B2 | Therapeutic use of mitochondria and combined mitochondrial agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6455210-B1 | SUPPORT, PHOTOTHERMOGRAPHIC IMAGE- RECEIVING LAYERS, AND ANTIHALATION LAYER OR FILTER LAYERS OF A DYE AND A HEXAARYLBIIMIDAZOLE IN A DISPERSION OF A HYDROPHILIC POLYMER | EASTMAN KODAK COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020106590-A1 | AQUEOUS THERMALLY BEACHABLE COMPOSITION USEFUL IN A PHOTOTHERMOGRAPHIC ELEMENT | CARESTREAM HEALTH, INC. | 2002-08-08 | — | — | US | disclosed |
| EP-1217431-A2 | An aqueous thermally bleachable composition useful in a photothermographic element | EASTMAN KODAK COMPANY (US) | 2002-06-26 | — | — | EP | disclosed |
| US-4201588-A | NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, CARBAZIDES OR QUINONES AS PHOTOREDUCTANT; EXTERNAL HYDROGEN SOURCE | EASTMAN KODAK COMPANY (US) | 1980-05-06 | — | — | US | disclosed |
| US-4201590-A | Heat sensitive reactive products of hexaarylbiimidazole and antihalation dyes | EASTMAN KODAK COMPANY (US) | 1980-05-06 | — | — | US | disclosed |
| US-4196002-A | HEXAARYLBISMIIDAZOLE, COLORLESS | EASTMAN KODAK COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4143049-A | METHOD FOR PREPARING 2H-TETRAZOLIUM CHLORIDE AND 2H-TETRAZOLIUM CHLORIDE HYDROCHLORIDE | OSTROVSKAYA VERA M | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041481-A1 | METHODS FOR CONTROLLING TREATMENT VOLUMES, THERMAL GRADIENTS, MUSCLE STIMULATION, AND IMMUNE RESPONSES IN PULSED ELECTRIC FIELD TREATMENTS | TNNC1, TNNT2, MUSK | RAB9A 2346/4885L3MBTL1 1476/4885NPC1 4184/4885 |
| US-20260014293-A1 | HEMOSTATIC AGENT IN PASTE FORM, USE THEREOF, AND METHOD FOR PRODUCING A LOCAL ACTIVE AGENT RELEASE SYSTEM | F9, PLAT, F12 | RAB9A 861/4885L3MBTL1 2310/4885NPC1 815/4885 |
| US-12599429-B2 | Methods for controlling treatment volumes, thermal gradients, muscle stimulation, and immune responses in pulsed electric field treatments | TNNC1, TNNT2, TNNI3 | RAB9A 3368/4885L3MBTL1 2977/4885NPC1 4671/4885 |
| US-12600800-B2 | Therapeutic use of mitochondria and combined mitochondrial agents | FECH, UQCRC2, ATP5PD | RAB9A 2257/4885L3MBTL1 1308/4885NPC1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.